(NTLA) Intellia Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.874m USD | Total Return: 69.3% in 12m

Gene Editing, CRISPR Technology, In Vivo Therapies, Ex Vivo Therapies
Total Rating 37
Safety 27
Buy Signal -0.09
Biotechnology
Industry Rotation: -4.2
Market Cap: 1.87B
Avg Turnover: 84.5M
Risk 3d forecast
Volatility76.1%
VaR 5th Pctl12.7%
VaR vs Median1.17%
Reward TTM
Sharpe Ratio1.02
Rel. Str. IBD81.7
Rel. Str. Peer Group56.3
Character TTM
Beta1.904
Beta Downside2.221
Hurst Exponent0.583
Drawdowns 3y
Max DD86.36%
CAGR/Max DD-0.36
CAGR/Mean DD-0.56
EPS (Earnings per Share) EPS (Earnings per Share) of NTLA over the last years for every Quarter: "2021-03": -0.69, "2021-06": -1.01, "2021-09": -0.97, "2021-12": -1.09, "2022-03": -1.96, "2022-06": -1.33, "2022-09": -1.49, "2022-12": -1.4, "2023-03": -1.17, "2023-06": -1.4, "2023-09": -1.38, "2023-12": -1.46, "2024-03": -1.12, "2024-06": -1.52, "2024-09": -1.34, "2024-12": -1.27, "2025-03": -1.1, "2025-06": -0.98, "2025-09": -0.92, "2025-12": -0.83, "2026-03": -0.81,
EPS CAGR: 29.35%
EPS Trend: 78.0%
Last SUE: 0.58
Qual. Beats: 0
Revenue Revenue of NTLA over the last years for every Quarter: 2021-03: 6.445, 2021-06: 6.55, 2021-09: 7.204, 2021-12: 12.854, 2022-03: 11.252, 2022-06: 14.03, 2022-09: 13.266, 2022-12: 13.573, 2023-03: 12.606, 2023-06: 13.594, 2023-09: 11.992, 2023-12: -1.917, 2024-03: 28.935, 2024-06: 6.957, 2024-09: 9.111, 2024-12: 12.874, 2025-03: 16.627, 2025-06: 14.245, 2025-09: 13.782, 2025-12: 23.017, 2026-03: 15.048,
Rev. CAGR: 1.89%
Rev. Trend: 13.0%
Last SUE: 0.14
Qual. Beats: 0

Warnings

Altman Z'' -15.00 < 1.0 - financial distress zone

Tailwinds

Confidence

Description: NTLA Intellia Therapeutics

Intellia Therapeutics, Inc. (NTLA) is a clinical-stage biotechnology company specializing in CRISPR/Cas9-based genome editing. The firm utilizes a modular platform to develop both in vivo therapies, which edit genes directly inside the human body, and ex vivo therapies, where cells are edited outside the body before being re-administered to the patient. Its primary clinical pipeline targets transthyretin amyloidosis and hereditary angioedema, with additional programs focused on immuno-oncology and autoimmune diseases.

The biotechnology sector often relies on strategic partnerships to mitigate high research and development costs while accelerating clinical timelines. Intellia maintains several collaborative agreements with industry peers, including Regeneron Pharmaceuticals and Kyverna Therapeutics, to co-develop CAR-T cell therapies and genomic medicines for conditions such as cystic fibrosis. This business model leverages external expertise and capital to expand the application of its CRISPR technology across diverse therapeutic areas.

Investors can further examine the companys valuation metrics and pipeline progress on ValueRay. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company continues to advance gene-editing delivery systems targeting organs beyond the liver to address significant unmet medical needs.

Headlines to Watch Out For
  • Phase 3 clinical trial results for NTLA-2001 determine long-term commercial viability
  • Regulatory approval milestones for NTLA-2002 drive near-term valuation shifts
  • Strategic collaboration revenue from Regeneron offsets high research and development burn
  • Intellectual property litigation outcomes impact CRISPR Cas9 platform licensing rights
  • Expansion of pipeline beyond liver-targeted therapies influences long-term growth expectations
Piotroski VR‑10 (Strict) 0.0
Net Income: -394.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.48 > 0.02 and ΔFCF/TA -9.27 > 1.0
NWC/Revenue: 590.1% < 20% (prev 962.9%; Δ -372.8% < -1%)
CFO/TA -0.48 > 3% & CFO -363.2m > Net Income -394.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.10 > 1.5 & < 3
Outstanding Shares: last quarter (118.5m) vs 12m ago 14.48% < -2%
Gross Margin: -31.89% > 18% (prev 0.83%; Δ -3.27k% > 0.5%)
Asset Turnover: 7.58% > 50% (prev 4.62%; Δ 2.95% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.51 (Total Current Assets 466.4m - Total Current Liabilities 76.4m) / Total Assets 758.8m
B: -3.54 (Retained Earnings -2.69b / Total Assets 758.8m)
C: -0.47 (EBIT TTM -407.6m / Avg Total Assets 872.5m)
D: -19.49 (Book Value of Equity -2.69b / Total Liabilities 137.8m)
Altman-Z'' Score: -31.77 = D
Beneish M -3.10
DSRI: 0.60 (Receivables 9.13m/10.5m, Revenue 66.1m/45.6m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.95 (AQ_t 0.24 / AQ_t-1 0.25)
SGI: 1.45 (Revenue 66.1m / 45.6m)
TATA: -0.04 (NI -394.6m - CFO -363.2m) / TA 758.8m)
Beneish M-Score: -3.10 (Cap -4..+1) = AA
What is the price of NTLA shares? As of May 17, 2026, the stock is trading at USD 13.67 with a total of 14,826,367 shares traded.
Over the past week, the price has changed by -2.98%, over one month by -8.50%, over three months by +11.87% and over the past year by +69.29%.
Is NTLA a buy, sell or hold? Intellia Therapeutics has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy NTLA.
  • StrongBuy: 18
  • Buy: 4
  • Hold: 6
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the NTLA price?
Analysts Target Price 26.6 94.2%
Intellia Therapeutics (NTLA) - Fundamental Data Overview as of 17 May 2026
P/S = 28.3707
P/B = 2.4959
P/EG = -0.0969
Revenue TTM = 66.1m USD
EBIT TTM = -407.6m USD
EBITDA TTM = -397.6m USD
Long Term Debt = 93.3m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 19.1m USD (from shortTermDebt, last quarter)
Debt = 112.4m USD (corrected: LT Debt 93.3m + ST Debt 19.1m)
Net Debt = -263.6m USD (recalculated: Debt 112.4m - CCE 376.0m)
Enterprise Value = 1.61b USD (1.87b + Debt 112.4m - CCE 376.0m)
 Interest Coverage Ratio = unknown (Ebit TTM -407.6m / Interest Expense TTM 0.0)
 EV/FCF = -4.43x (Enterprise Value 1.61b / FCF TTM -363.6m)
FCF Yield = -22.57% (FCF TTM -363.6m / Enterprise Value 1.61b)
 FCF Margin = -550.2% (FCF TTM -363.6m / Revenue TTM 66.1m)
 Net Margin = -597.0% (Net Income TTM -394.6m / Revenue TTM 66.1m)
 Gross Margin = -31.89% ((Revenue TTM 66.1m - Cost of Revenue TTM 87.2m) / Revenue TTM)
Gross Margin QoQ = 85.37% (prev 73.87%)
Tobins Q-Ratio = 2.12 (Enterprise Value 1.61b / Total Assets 758.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 112.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -322.0m (EBIT -407.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.10 (Total Current Assets 466.4m / Total Current Liabilities 76.4m)
Debt / Equity = 0.18 (Debt 112.4m / totalStockholderEquity, last quarter 620.9m)
 Debt / EBITDA = 0.66 (negative EBITDA) (Net Debt -263.6m / EBITDA -397.6m)
 Debt / FCF = 0.72 (negative FCF - burning cash) (Net Debt -263.6m / FCF TTM -363.6m)
 Total Stockholder Equity = 689.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.23% (Net Income -394.6m / Total Assets 758.8m)
RoE = -57.27% (Net Income TTM -394.6m / Total Stockholder Equity 689.0m)
RoCE = -52.11% (EBIT -407.6m / Capital Employed (Equity 689.0m + L.T.Debt 93.3m))
 RoIC = -45.25% (negative operating profit) (NOPAT -322.0m / Invested Capital 711.7m)
 WACC = 11.96% (E(1.87b)/V(1.99b) * Re(12.68%) + D(112.4m)/V(1.99b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 12.75%
 [DCF] Fair Price = unknown (Cash Flow -363.6m)
 EPS Correlation: 77.98 | EPS CAGR: 29.35% | SUE: 0.58 | # QB: 0
Revenue Correlation: 13.00 | Revenue CAGR: 1.89% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.81 | Chg30d=+9.43% | Revisions=+33% | Analysts=15
EPS next Quarter (2026-09-30): EPS=-0.82 | Chg30d=+9.18% | Revisions=+33% | Analysts=15
EPS current Year (2026-12-31): EPS=-3.31 | Chg30d=+7.05% | Revisions=+14% | GrowthEPS=+13.2% | GrowthRev=-8.3%
EPS next Year (2027-12-31): EPS=-1.88 | Chg30d=+35.49% | Revisions=+11% | GrowthEPS=+43.0% | GrowthRev=+345.9%
[Analyst] Revisions Ratio: +33%